SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.

Start Date01 Jun 2025

Sponsor / Collaborator

Beth Israel Deaconess Medical Center, Inc.

NCT06055179

/ RecruitingNot ApplicableIIT

Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang (XCHT) Against Irinotecan-Induced Gut Toxicities(Clinical Study Part:Randomized Controlled Trial)

Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.

Start Date08 Mar 2024

Sponsor / Collaborator

Guangzhou University of Chinese Medicine

[+1]

CTR20213368

/ CompletedNot Applicable

盐酸雷洛昔芬片在健康成年受试者中单次空腹及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验方案

[Translation] A randomized, open-label, two-period, two-sequence, crossover bioequivalence study of raloxifene hydrochloride tablets in healthy adult subjects after single oral administration on an empty stomach or after a high-fat meal

研究重庆圣华曦药业股份有限公司生产的盐酸雷洛昔芬片（规格：60mg）在中国健康受试者中空腹及高脂餐后以口服途径单次给药的药代动力学特征，并以Eli Lilly Nederland B.V持有Lilly,S.A.生产的盐酸雷洛昔芬片（商品名：EVISTA®；规格：60mg）为参比制剂，进行生物等效性评价。考察盐酸雷洛昔芬片受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

The pharmacokinetic characteristics of raloxifene hydrochloride tablets (specification: 60 mg) produced by Chongqing Shenghuaxi Pharmaceutical Co., Ltd. were studied after a single oral administration in Chinese healthy subjects on an empty stomach and after a high-fat meal. The bioequivalence evaluation was performed using raloxifene hydrochloride tablets (trade name: EVISTA®; specification: 60 mg) produced by Lilly, S.A. owned by Eli Lilly Nederland B.V. as the reference preparation. The safety of the test preparation and reference preparation of raloxifene hydrochloride tablets in healthy subjects was investigated.

Start Date21 Dec 2021

Sponsor / Collaborator

Chongqing Shenghuaxi Pharmaceutical Co. Ltd.

100 Clinical Results associated with Raloxifene Hydrochloride

100 Translational Medicine associated with Raloxifene Hydrochloride

100 Patents (Medical) associated with Raloxifene Hydrochloride

5,687

Literatures (Medical) associated with Raloxifene Hydrochloride

01 Jun 2025·Bone Reports

Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption

Article

Author: Croft, S M ; Castillo, E J ; Kimmel, D B ; Cruz-Camacho, C J ; Aguirre, J I

Medication-Related-Osteonecrosis-of-the-Jaw (MRONJ) is an adverse event linked to antiresorptives such as bisphosphonates and denosumab. While MRONJ predominantly affects cancer patients treated with these agents, it has been less frequently reported in cancer patients receiving angiogenesis inhibitors (AgIs) like bevacizumab and sunitinib, even without concurrent use of antiresorptives. We hypothesized that certain AgIs exhibit antiresorptive activity in addition to their antiangiogenic effects, potentially influencing the pathophysiology of MRONJ. 52 five-week-old SD rats were randomized to receive vehicle (VEH), an oncologic dose of zoledronic acid (ZOL), or low (LD) and high doses (HD) of either an anti-VEGFA antibody or sunitinib (SU) for 10 days. We used the Schenk assay to assess the in vivo antiresorptive properties of these drugs/agents. We evaluated serum biomarkers of bone resorption (TRACP 5b) and formation (P1NP), pQCT variables of the femurs/tibias, and bone resorption/formation variables by bone histomorphometry at the distal femur metaphysis. ZOL reduced TRACP-5b levels, osteoclast number, and BFR while increasing vBMD, mineralized tissue volume, calcified cartilage volume, and bone volume. Both anti-VEGFA and SU decreased osteoclast number and increased calcified cartilage volume relative to total mineralized tissue volume, though to a lesser extent than ZOL. Anti-VEGFA (HD) also reduced TRACP-5b levels. Furthermore, both AgIs decreased P1NP levels, MAR, and bone elongation rate but increased growth cartilage thickness and induced physeal dysplasia. In conclusion, AgIs, particularly anti-VEGFA, exhibit significant yet milder antiresorptive activity compared to ZOL. They also affect bone formation, suggesting a complex mechanism that may play a role in the pathophysiology of MRONJ.

01 Jun 2025·Journal of the Mechanical Behavior of Biomedical Materials

A measure of intrinsic strength, not nominal strength, reflects effects of ex-vivo cortical bone matrix modulation by raloxifene

Article

Author: Pyrak-Nolte, Laura J ; Wallace, Joseph M ; Siegmund, Thomas ; Howarter, John ; Surowiec, Rachel K ; Arnhart, Mary ; Allen, Matthew R

Understanding bone strength is important when assessing bone diseases and their treatment. Bending experiments are often used to determine strength. Then, flexural stresses are calculated from elastic bending theory. With a brittle failure criterion, the maximum flexural tensile stress is equated to (nominal) strength. However, bone is not a perfectly brittle material. A quasi-brittle failure criterion is more appropriate. Such an approach allows for material failure to occur before full fracture. The extent of the subcritical damage domain then introduces a length scale. The intrinsic strength of the bone is calculated from the critical load at fracture and the failure process zone dimensions relative to the specimen size. We apply this approach to human cortical bone specimens extracted from a femur. We determine strength measures in the untreated reference state and after treatment with the selective estrogen receptor modulator raloxifene. We find that the common nominal strength measure does not distinguish between treatments. However, the dimensions of the failure process zone differ between treatments. Intrinsic strength measures then are demonstrated as descriptors of bone strength sensitive to treatment. An extrapolation of laboratory data to whole bone is demonstrated.

01 May 2025·EXPERIMENTAL PARASITOLOGY

In silico screening and molecular dynamic simulations of FDA-approved drugs as an inhibitor of trypanothione reductase of Leishmania donovani

Article

Author: Medhi, Bikash ; Sehgal, Rakesh ; Prakash, Ajay ; Bhusal, Chandra Kanta ; Beniwal, Pooja ; Choudhary, Gajendra ; Kaur, Sukhbir

Visceral leishmaniasis (VL) is mainly caused by Leishmania donovani (Ld) and Leishmania (L.) infantum, and it is prevalent in Brazil, India and East Africa. VL is a serious health issue, affecting millions of people worldwide and causing thousands of deaths annually. The current treatments for leishmaniasis are inadequate because of their low efficacy, toxicity and growing resistance, underscoring the pressing need to explore new drugs. Among the various molecular targets explored, trypanothione reductase (TR) is of special relevance because of its crucial function in regulating the parasite's redox homeostasis. Inhibiting TR can disrupt the redox homeostasis of the parasites, offering a promising strategy for developing new drugs with improved efficacy and safety profiles. In this study, 3D structure model of TR was elucidated by homology modelling and potential novel inhibitors against Leishmania donovani TR (LdTR) were identified by performing high-throughput virtual screening of 1615 FDA-approved drugs from the ZINC database via molecular docking, selecting top ligands on the basis of their high binding score and number of hydrogen bonds. These best hits are further subjected to Molecular Dynamics (MD) simulation and Molecular Mechanics Poisson- Boltzmann Surface Area (MM-PBSA) analysis. The results indicated that the binding scores of Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin are -10.9 and -10.6, -10.1, -9.7 and -9.6 kcal/mol respectively. The lead compounds i.e. Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin complexes with our target TR were found to be stable during MD simulation studies. Furthermore, MM-PBSA analysis demonstrated that these compounds had a high negative binding free energy. Thus, in-silico results showed that Dasatinib, Regorafenib, Bicalutamide and Raloxifene and Silodosin seem to have efficacy against TR for the treatment of VL. With further in vitro and in vivo investigations Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin could be a good candidate of choice for combating leishmaniasis.

News (Medical) associated with Raloxifene Hydrochloride

10 Sep 2024

·www.drugs.com

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

Clinical Result

24 May 2023

·www.biospace.com

New Data Reveal Role of SARS-Cov-2 Spike Protein in Covid-19 Associated Coagulopathy

Unprecedented comprehension of the interaction between Spike and the Human Estrogen Receptor Alfa provides insights for a new generation of anti SARS-CoV-2 and pan-Coronavirus vaccines Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)-- Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COVID-19 vaccines. This press release features multimedia. View the full release here: Framework Dompé farmaceutici Biotech production (Photo: Business Wire) Data stemmed from the EXSCALATE supercomputing calculation predicted a potential function of Spike (S) as a co-factor for human ERα nuclear signalling. This interaction is mediated by a nuclear receptor co-regulator (NRC) LXD-like motif present on the viral protein S2 subunit, and the activation function 2 (AF-2) region on ERα2. This work builds on other recent studies3,4 showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα. While circulating estrogens play a protective role by regulating the immune response to infection, modulation of ERα signalling in SARS-CoV-2-infected lung tissue stimulates proinflammatory signals leading to hypertrophy, vasoconstriction, and vessel obstruction. In the new article the scientists of the italo-american collaboration (encompassing Centro Cardiologico Monzino in Italy and the National Institute on Drug Abuse and the Johns Hopkins School of Medicine in the US) demonstrated that the interaction between the Spike protein and ERα leads to an increase in tissue factor (TF) and the overall pro-coagulation activity in two human endothelial cell lines. The results were further validated by overexpressing S-protein in mice. This pro-coagulative function of Spike in vitro and in vivo, was abolished or strongly reduced by the variants of the Spike proteins carrying mutations in the interaction domain with ERα (as predicted by EXSCALATE). “The value and benefits of vaccines in countering the COVID-19 pandemic remain unquestionable and overwhelming compared to the risks associated with infection from SARS-CoV-2” underscores Maurizio Pesce, a research Group Leader at the Monzino Cardiology Center in Milan, Italy, and initiator of the study in 2021 together with the leading Silvia Barbieri, another research Group Leader at Monzino, “We hope that our findings will be considered in the development of the next generation of vaccines reducing the residual side effects and risks. Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors. This has general implications not only for COVID-19, but for other viral infections altering the coagulation pro patients”. “This continuing research is critical to understand the pathogenetic mechanisms associated with SARS-CoV2 infection and causal mechanisms of some rare COVID-19 vaccine side effects,” says Dompé farmaceutici Chief Scientific Officer Marcello Allegretti “Ongoing expanding data is revealing a well-conserved region with the same characteristics of the LXD-like motif present on the viral protein S2 subunit, also in other Coronaviruses. This evidence could open new scenarios in ‘pan-Coronavirus’ vaccination. We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”. ____________________________________________________________________________________ About Dompé Dompé is a private, rapidly scaling international biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The R&D department of the company is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world. Today, Dompé employs more than 800 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston. Forward Looking Statements This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompé cannot guarantee that the expected results will be consistent with the information provided above. 1. SS Barbieri et al. Relevance of the viral Spike protein/cellular Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2 - Signal Transduction and Targeted Therapy - 2. Allegretti, M. et al. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 370 infection. Cell Death Differ. 29, 156-166 (2022). 371 - 3. Wilcox et al. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19, Am J Cardiol. 2022 May 1; 170: 112–117 - 4. Science Advances - The SARS-CoV-2 spike protein binds and modulates estrogen receptors - eadd4150 (2022) 30 November 2022 -

Vaccine

24 May 2023

·www.dompe.com

New Data Reveal Role of SARS-Cov-2 Spike protein in Covid-19 associated coagulopathy

Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. MILAN, Italy and SAN MATEO, Calif. | 22 May, 2023 - Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation [1]. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COVID-19 vaccines. Data stemmed from the EXSCALATE supercomputing calculation predicted a potential function of Spike (S) as a co-factor for human ERα nuclear signalling. This interaction is mediated by a nuclear receptor co-regulator (NRC) LXD-like motif present on the viral protein S2 subunit, and the activation function 2 (AF-2) region on ERα [2]. This work builds on other recent studies [3], [4] showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα. While circulating estrogens play a protective role by regulating the immune response to infection, modulation of ERα signalling in SARS-CoV-2-infected lung tissue stimulates proinflammatory signals leading to hypertrophy, vasoconstriction, and vessel obstruction. In the new article the scientists of the italo-american collaboration (encompassing Centro Cardiologico Monzino in Italy and the National Institute on Drug Abuse and the Johns Hopkins School of Medicine in the US) demonstrated that the interaction between the Spike protein and ERα leads to an increase in tissue factor (TF) and the overall pro-coagulation activity in two human endothelial cell lines. The results were further validated by overexpressing S-protein in mice. This pro-coagulative function of Spike in vitro and in vivo, was abolished or strongly reduced by the variants of the Spike proteins carrying mutations in the interaction domain with ERα (as predicted by EXSCALATE). “The value and benefits of vaccines in countering the COVID-19 pandemic remain unquestionable and overwhelming compared to the risks associated with infection from SARS-CoV-2” underscores Maurizio Pesce, a research Group Leader at the Monzino Cardiology Center in Milan, Italy, and initiator of the study in 2021 together with the leading Silvia Barbieri, another research Group Leader at Monzino, “We hope that our findings will be considered in the development of the next generation of vaccines reducing the residual side effects and risks. Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors. This has general implications not only for COVID-19, but for other viral infections altering the coagulation profile of patients”. “This continuing research is critical to understand the pathogenetic mechanisms associated with SARS-CoV2 infection and causal mechanisms of some rare COVID-19 vaccine side effects,” says Dompé farmaceutici Chief Scientific Officer Marcello Allegretti “Ongoing expanding data is revealing a well-conserved region with the same characteristics of the LXD-like motif present on the viral protein S2 subunit, also in other Coronaviruses. This evidence could open new scenarios in ‘pan-Coronavirus’ vaccination. We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”. [1] SS Barbieri et al. Relevance of the viral Spike protein/cellular Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2 - Signal Transduction and Targeted Therapy [2] Allegretti, M. et al. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 370 infection. Cell Death Differ. 29, 156-166 (2022). 371 [3] Wilcox et al. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19, Am J Cardiol. 2022 May 1; 170: 112–117 [4] Science Advances - The SARS-CoV-2 spike protein binds and modulates estrogen receptors - eadd4150 (2022) 30 November 2022

Vaccine

100 Deals associated with Raloxifene Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02217	Raloxifene Hydrochloride	G03XC01	DB00481

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	United States	Eli Lilly & Co.	13 Sep 2007
Osteoporosis, Postmenopausal	United States	Eli Lilly & Co.	09 Dec 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	France	Dompe Farmaceutici SpA	22 Jan 2021
COVID-19	Phase 3	Italy	Dompe Farmaceutici SpA	22 Jan 2021
COVID-19	Phase 3	Spain	Dompe Farmaceutici SpA	22 Jan 2021
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Coronary Disease	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Invasive Mammary Carcinoma	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Hemorrhagic Fever, Ebola	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hepatitis B	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hepatitis C, Chronic	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Zika Virus Infection	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ODP119 (ENDO2022)	Not Applicable	Osteoporosis, Postmenopausal	66	Raloxifene users	rknzxfoeel(snpbcnxfkf) = jqlukbtbvn pobxxhvrje (djpabxuckq )	Positive	01 Nov 2022
DDW2022	Not Applicable	Osteoporosis, Postmenopausal	-	Raloxifene	duqnntczxq(mozgcmycis): OR = 1.854 (95% CI, 1.643 - 2.092) View more	Negative	24 May 2022
				No Raloxifene
DDW2022	Not Applicable	Osteoporosis, Postmenopausal	-	Raloxifene	wjkfxnocef(hngfgzjfdb): OR = 1.854 (95% CI, 1.643 - 2.092) View more	-	24 May 2022
				No Raloxifene
DDW2022	Not Applicable	Osteoporosis, Postmenopausal	-	Raloxifene	eaxxbojqmc(zjjkzjhskc): OR = 1.854 (95% CI, 1.643 - 2.092) View more	-	24 May 2022
				No Raloxifene
DDW2022	Not Applicable	Osteoporosis, Postmenopausal	-	Raloxifene	asornjednn(ethnevqdpn): OR = 1.854 (95% CI, 1.643 - 2.092) View more	-	24 May 2022
				No Raloxifene
DDW2022	Not Applicable	Osteoporosis, Postmenopausal	-	Raloxifene	ioschtgcwd(hidctaxdgt): OR = 1.854 (95% CI, 1.643 - 2.092) View more	Negative	24 May 2022
				No Raloxifene
P0903 (ERA2020)	Not Applicable	Chronic Kidney Diseases	39,128	Osteoporosis medications (bisphosphonates, raloxifene, teriparatide, or denosumab)	lwufkyvwpv(ftqluuyqeb) = nspwazyiaj dfohczzyjy (jeyqrdvkgi ) View more	Negative	06 Jun 2020
2020 ARVO Annual Meeting (ARVO2020)	Phase 2	Brain Injuries, Traumatic	-	Raloxifene 5 mg/kg	eerknfurdh(gulhjpheph) = reduced or eliminated byganewdln (yrfxverakv ) View more	Positive	01 Jun 2020
				Raloxifene 10 mg/kg
NCT00687102 (Co-STAR, CTgov)	Phase 3	Cognition	1,498	tamoxifen (Star Participants Assigned to Tamoxifen)	zbqlgohovx(dgiorczwnq) = wtgxvvqbhv wzwmjindgc (fgcusnjxww, 0.34) View more	-	23 Jan 2018
				raloxifene (Star Participants Assigned to Raloxifene)	zbqlgohovx(dgiorczwnq) = kiojhpnmxj wzwmjindgc (fgcusnjxww, 0.32) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis